Los Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Los Angeles Capital Management LLC grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 159.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 200,282 shares of the biopharmaceutical company's stock after buying an additional 123,020 shares during the period. Los Angeles Capital Management LLC owned about 0.17% of Catalyst Pharmaceuticals worth $3,982,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of CPRX. Vanguard Group Inc. raised its stake in shares of Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company's stock worth $127,212,000 after purchasing an additional 860,244 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Catalyst Pharmaceuticals by 9.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company's stock valued at $46,479,000 after purchasing an additional 263,099 shares during the last quarter. Pacer Advisors Inc. raised its position in Catalyst Pharmaceuticals by 130,918.8% in the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company's stock worth $45,968,000 after acquiring an additional 2,965,310 shares during the period. Janus Henderson Group PLC lifted its position in shares of Catalyst Pharmaceuticals by 139.5% during the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company's stock worth $43,445,000 after acquiring an additional 1,587,794 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Catalyst Pharmaceuticals by 15.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company's stock valued at $33,702,000 after acquiring an additional 287,300 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company's stock.

Insiders Place Their Bets

In other news, insider Steve Miller sold 150,000 shares of the firm's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the sale, the insider now directly owns 675,124 shares in the company, valued at approximately $13,738,773.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now owns 675,124 shares in the company, valued at $13,738,773.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the sale, the director now owns 348,874 shares in the company, valued at $7,012,367.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Citigroup boosted their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Monday. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 9th. Finally, HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $30.50.

Catalyst Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ:CPRX traded down $0.24 during trading on Wednesday, reaching $22.80. The stock had a trading volume of 895,144 shares, compared to its average volume of 1,194,271. The stock has a market cap of $2.72 billion, a P/E ratio of 19.32, a PEG ratio of 3.67 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $12.90 and a fifty-two week high of $24.27. The business has a fifty day moving average price of $20.93 and a 200-day moving average price of $18.26.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.